Blackwork / Blackout tattoo by Pol B - No Way Back - Toronto - Canada #tattoo #polb #blackwork #blackworktattoo #toronto #canada #blackout #blackouttattoo #abstracttattoo #paintbrushes

POLB 001 is a potential preventative therapy targeting cancer immunotherapy-induced CRS. Did you know, key opinion leaders were supportive of its significant potential? Check out what the KOL’s had to say… #POLB #Poolbeg #KeyOpinionLeaders #Bispecific #CART #Cancer

During our panel discussion at the @_investorsummit our CEO Jeremy Skillington discussed the benefits of Orphan Drug Designation (ODD) and how this award from the FDA significantly benefits POLB 001’s development. 👉7-year U.S. market exclusivity 💪Tax benefits for clinical

How much revenue could POLB 001 generate? 💰 “If the drug is successful, it could easily be several billion dollars” as said by panellist Brian White 🏥Cost of getting people out of hospital setting 🔬Treating current bottle neck which CRS creates 👉POLB 001 is a CRS

#POLB Poolbeg Pharma PLC - POLB 001 Phase 2a Trial Update - Signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials LTD ("ACT") - Along with supply of an approved bispecific antibody drug for the trial. https://t.co/3wh5uVnam3

Following this morning’s announcement, we will be presenting with @InvestorMeetCo Join Poolbeg’s CEO Jeremy Skillington and Principal Scientist Liam Tremble who will discuss the upcoming POLB 001 Phase 2a trial which will be conducted by ACT, having secured the supply of an

We have signed an agreement for Accelerating Clinical Trials Limited (ACT) to conduct the upcoming POLB 001 Phase 2a trial & have secured supply of an approved bispecific antibody drug for the trial at no cost to the Company. 💡 POLB 001 has the potential to transform the

Our CEO shares the highlights from our POLB 001 Trial update & Interim results: 🤝 Agreement signed with specialist blood cancer trial organisation – Accelerating Clinical Trials 💊Approved bispecific antibody drug secured for the trial at no cost to the Company 🏥Trial to

Tune into our snippet from CEO Jeremy Skillington, who provides a timeline for POLB 001’s milestones ✅Trial to commence before the end 2025 ☑️Interim data in H1 2026 🚀Trial completion by H2 2026 🤝Take datasets, intellectual property to partnering with Big Pharma ➡️ODD

At Poolbeg Pharma we have identified a significant market opportunity in oncology for POLB 001 expected to exceed US$10 billion due to the rapid advancements in bispecific antibody and CAR T cell therapies. Currently, no therapies are approved for the prevention of Cytokine

Our CEO highlights how many treatments are available for the treatment of CRS and how POLB 001 compares as a preventative therapy. 👉 “Surprisingly very few” treatments available 🏥 Preventing CRS has the potential to expand administration of cancer immunotherapies from

On the move: #POLB 👀 @PoolbegPharma is targeting multi-$B markets with cutting-edge programmes in: 💉 Cancer immunotherapy (CRS prevention) ⚖️ Obesity (oral GLP-1 breakthrough) 🦠 Infectious diseases & AI drug discovery ✅ FDA Orphan Drug Designation ✅ Phase 2 ready 🚦 ✅

Our recent news on the signed agreement with Accelerating Clinical Trials (ACT) to run the Phase 2a trial for POLB 001 was covered by @DDWJournal Drug Discovery World 🔹~30 patients across leading UK cancer centres 🔹Led by Dr Emma Searle at The Christie NHS Foundation Trust &

So many strategies with $BTN You could mint $BTCb with $ada and $BTN. Use half of $BTCb to get an ada loan and then use remaining half of BTCb and loan ada to mint POLb. Sell $POLb for usdb. Sell $usdb for $ada. Sell half $ada for $BTN, and mint more $BTCb. BTC long🤣🤣🤣

Poolbeg Pharma CEO on active H1, POLB 001 & GLP-1 trial plans @PoolbegPharma https://t.co/ZbFFVnO5bi #Health #Pharmaceuticals #Biotech #Cancer #Oncology #GLP1

Our CEO joined Jo Shorthouse on the @Citeline In Vivo podcast, which focuses on perspectives on commercial strategy, deal-making, R&D trends and other key commercial topics. 💡 Jeremy's experience & career highlights 🔬 Overview of Poolbeg Pharma 💊 Lead asset POLB 001: Oral

Video footage of containers falling from vessel Mississippi taken by @uscg Sector LA-LB Incident Management Division while on scene. #longbeach #vesselmississippi #polb #uscg

Our Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble caught up with @VOXmarkets on this mornings update on the POLB 001 Phase 2a trial ✅ Approved bispecific antibody drug supply secured at no cost to Poolbeg 👉 Trial to be conducted by specialist

🔥 @PoolbegPharma (#POLB) – one to watch •🎯 Targeting cancer CRS & obesity (oral GLP-1) •💰 Oversubscribed raise (May ‘25) – runway into 2027 •🚀 Fully funded for near-term value inflection points •🤝 Partnering focus – big pharma appeal Innovative meds for HUGE unmet